Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 149

Sort by

Sort Order Select

Journal Articles

Different kinetic behavior of molecular reduction by BCR::ABL1 transcript types in frontline treatment of chronic myeloid leukemia patients: A GIMEMA labnet CML network database survey.

Blood (2025) 146 (Supplement 1): 3755.

https://doi.org/10.1182/blood-2025-3755

Published: 2025

Journal Articles

Molecular predictors of survival in patients with myeloproliferative neoplasm-blast Phase (MPN-BP) treated with venetoclax and decitabine

Paola Guglielmelli, Francesca Crupi, Mirko Lomi, Francesco Mannelli, Jessica Caroprese, Niccolò Bartalucci, Stefano Soddu, Chiara Maccari, Alessio Enderti, Daniele Colazzo, leonardo Signori, Giada Rotunno, Alfonso Piciocchi, Giuseppe Gaetano Loscocco, Sara Bianchini, Elena Nacca, Paola Fazi, Marco Vignetti, Alessandro Vannucchi

Blood (2025) 146 (Supplement 1): 3751.

https://doi.org/10.1182/blood-2025-3751

Published: 2025

Journal Articles

Venetoclax and decitabine in myeloproliferative neoplasm-blast Phase (MPN-BP): Results of enable, a gimema and airc-mynerva multicenter, Phase 2 trial

Blood (2025) 146 (Supplement 1): 1025.

https://doi.org/10.1182/blood-2025-1025

Published: 2025

Journal Articles

The prognostic value for survival of frailty and patient-reported outcomes in relapsed/refractory multiple myeloma: Results from a prospective multicenter observational study

Fabio Efficace, Gianluca Gaidano, Pasquale Niscola, Serena Puglia, Francesco Sparano, Katia Codeluppi, Elisabetta Antonioli, Catello Califano, Lajos Floro, Ombretta Annibali, Claudio Fozza, Agostino Tafuri, Patrizio Mazza, Leonardo Potenza, Marco Vignetti, Michele Cavo, Maria Teresa Petrucci

Blood (2025) 146 (Supplement 1): 138.

https://doi.org/10.1182/blood-2025-138

Published: 2025

Journal Articles

Socioeconomic inequalities and health-related quality of life profile of patients with Myelodysplastic Syndromes (MDS): Analysis of 504 patients with higher-risk MDS

Francesco Sparano, Giovanni Caocci, Pasquale Niscola, Gianluca Gaidano, Massimo Breccia, Reinhard Stauder, Uwe Platzbecker, Serena Puglia, Alessandra Ricco, Giuseppe Palumbo, Maria Teresa Voso, Frederic Baron, Marco Vignetti, Fabio Efficace

Blood (2025) 146 (Supplement 1): 6389.

https://doi.org/10.1182/blood-2025-6389

Published: 2025

Journal Articles

Health-related quality of life trajectories of patients with aggressive B-cell lymphomas treated with CAR T-cell therapy: Results from a prospective observational study

Blood (2025) 146 (Supplement 1): 6279.

https://doi.org/10.1182/blood-2025-6279

Published: 2025

Journal Articles

The prognostic value of patient-reported fatigue for survival in patients with aggressive B-cell lymphomas treated with CAR T-cell therapy

Blood (2025) 146 (Supplement 1): 6278.

https://doi.org/10.1182/blood-2025-6278

Published: 2025

Journal Articles

Acute promyelocytic leukemia: long-term outcomes from the HARMONY project

Blood (2025) 145 (2): 234–243.

https://doi.org/10.1182/blood.2024026186

Published: 2025

Includes: Supplemental data

Journal Articles

Centralized MRD Assessment in Gimema AML1718 Trial, a Phase 2 Open-Label Study of Venetoclax Combined with Intensified FLAI Chemotherapy (V-FLAI) As Induction Therapy of Non Low-Risk AML

Blood (2024) 144 (Supplement 1): 1574.

https://doi.org/10.1182/blood-2024-198139

Published: 2024

Journal Articles

Factors Predicting Short-Term Symptom Burden in Patients with Aggressive B-Cell Lymphomas Treated with CAR T-Cell Therapy: A Real-World Study By the Gimema

Blood (2024) 144 (Supplement 1): 7823.

https://doi.org/10.1182/blood-2024-199498

Published: 2024

Journal Articles

Molecular Outcome of Chronic Myeloid Leukemia Affected Patients Not in Deep Molecular Response: The “Others” from the Gimema Labnet Network

Blood (2024) 144 (Supplement 1): 992.

https://doi.org/10.1182/blood-2024-210201

Published: 2024

Journal Articles

Digital Twins As Control Groups to Accelerate Assessment of Safety and Efficacy of Novel Treatment Strategies in Ph-Negative Acute Lymphoblastic Leukemia

Alfonso Piciocchi, Monica Messina, Giovanni Marsili, Marta Cipriani, Francesca Paola Paoloni, Davide Lazzarotto, Anna Candoni, Alessandro Rambaldi, Matteo Leoncin, Paola Fazi, Marco Vignetti, Robin Foà, Sabina Chiaretti

Blood (2024) 144 (Supplement 1): 274.

https://doi.org/10.1182/blood-2024-200643

Published: 2024

Journal Articles

Identification of Genomic Structural Variants (SVs) with Adverse Prognostic Significance in Normal-Karyotype (nk) Acute Myeloid Leukemia (AML) Patients

Blood (2024) 144 (Supplement 1): 65.

https://doi.org/10.1182/blood-2024-198342

Published: 2024

Journal Articles

Survival Analysis of Gimema AML1718, a Safety Run-in and Phase 2 Open-Label Study of Venetoclax, Fludarabine, Idarubicin and Cytarabine (V-FLAI) in the Induction Therapy of Non Low-Risk Acute Myeloid Leukemia

Blood (2024) 144 (Supplement 1): 2891.

https://doi.org/10.1182/blood-2024-207842

Published: 2024

Journal Articles

Profiling Baseline Health-Related Quality of Life of Patients with Newly Diagnosed Myeloid Malignancies: A Pooled Analysis of 3349 Patients with AML, APL and MDS from the International Proactive Project

Fabio Efficace, Adriano Venditti, Thomas Baldi, Joanna Canham, Giovanni Martinelli, Alfonso Piciocchi, Mike Dennis, Steve Knapper, Nigel H. Russell, Sean Johnson, Maria Teresa Voso, Marco Vignetti, Ian Thomas

Blood (2024) 144 (Supplement 1): 407.

https://doi.org/10.1182/blood-2024-204588

Published: 2024

Journal Articles

The Prognostic Value for Survival of Self-Reported Fatigue in Patients with Newly Diagnosed Myelodysplastic Syndromes: An International Prospective Observational Study By the Gimema

Blood (2024) 144 (Supplement 1): 404.

https://doi.org/10.1182/blood-2024-204633

Published: 2024

Journal Articles

Evaluating the Impact of Cross-over from Imatinib to Nilotinib on the Overall Survival in Chronic Myeloid Leukemia Using Inverse Probability of Censoring Weighting: Results from the Gimema Sustrenim Study

Alfonso Piciocchi, Giovanni Marsili, Ylenia Belperio, Monica Messina, Francesca Paola Paoloni, Stefano Soddu, Isabella Capodanno, Rosaria Sancetta, Elisabetta Abruzzese, Alessandro Pulsoni, Monia Lunghi, Giovanni Caocci, Fausto Castagnetti, Paola Fazi, Marco Vignetti, Massimo Breccia, Fabrizio Pane

Blood (2024) 144 (Supplement 1): 4530.

https://doi.org/10.1182/blood-2024-198366

Published: 2024

Journal Articles

Decitabine in older patients with AML: quality of life results of the EORTC-GIMEMA-GMDS-SG randomized phase 3 trial

Blood (2024) 144 (5): 541–551.

https://doi.org/10.1182/blood.2023023625

Published: 2024

Includes: Supplemental data

Journal Articles

Real World Outcome of Unfit Patients with Acute Myeloid Leukemia Treated with the Combination Venetoclax Plus Hypomethylating Agents in the Gimema AML2320 Observational Trial

Blood (2023) 142 (Supplement 1): 1514.

https://doi.org/10.1182/blood-2023-178505

Published: 2023

Journal Articles

Health-Related Quality of Life Profile and Symptom Burden of Patients with Aggressive B-Cell Lymphomas Just before CAR-T-Cell Therapy: A Real-World Study By the Gimema

Blood (2023) 142 (Supplement 1): 7384.

https://doi.org/10.1182/blood-2023-180012

Published: 2023

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Different kinetic behavior of molecular reduction by BCR::ABL1 transcript types in frontline treatment of chronic myeloid leukemia patients: A GIMEMA labnet CML network database survey.

Molecular predictors of survival in patients with myeloproliferative neoplasm-blast Phase (MPN-BP) treated with venetoclax and decitabine

Venetoclax and decitabine in myeloproliferative neoplasm-blast Phase (MPN-BP): Results of enable, a gimema and airc-mynerva multicenter, Phase 2 trial

The prognostic value for survival of frailty and patient-reported outcomes in relapsed/refractory multiple myeloma: Results from a prospective multicenter observational study

Socioeconomic inequalities and health-related quality of life profile of patients with Myelodysplastic Syndromes (MDS): Analysis of 504 patients with higher-risk MDS

Health-related quality of life trajectories of patients with aggressive B-cell lymphomas treated with CAR T-cell therapy: Results from a prospective observational study

The prognostic value of patient-reported fatigue for survival in patients with aggressive B-cell lymphomas treated with CAR T-cell therapy

Acute promyelocytic leukemia: long-term outcomes from the HARMONY project

Centralized MRD Assessment in Gimema AML1718 Trial, a Phase 2 Open-Label Study of Venetoclax Combined with Intensified FLAI Chemotherapy (V-FLAI) As Induction Therapy of Non Low-Risk AML

Factors Predicting Short-Term Symptom Burden in Patients with Aggressive B-Cell Lymphomas Treated with CAR T-Cell Therapy: A Real-World Study By the Gimema

Molecular Outcome of Chronic Myeloid Leukemia Affected Patients Not in Deep Molecular Response: The “Others” from the Gimema Labnet Network

Digital Twins As Control Groups to Accelerate Assessment of Safety and Efficacy of Novel Treatment Strategies in Ph-Negative Acute Lymphoblastic Leukemia

Identification of Genomic Structural Variants (SVs) with Adverse Prognostic Significance in Normal-Karyotype (nk) Acute Myeloid Leukemia (AML) Patients

Survival Analysis of Gimema AML1718, a Safety Run-in and Phase 2 Open-Label Study of Venetoclax, Fludarabine, Idarubicin and Cytarabine (V-FLAI) in the Induction Therapy of Non Low-Risk Acute Myeloid Leukemia

Profiling Baseline Health-Related Quality of Life of Patients with Newly Diagnosed Myeloid Malignancies: A Pooled Analysis of 3349 Patients with AML, APL and MDS from the International Proactive Project

The Prognostic Value for Survival of Self-Reported Fatigue in Patients with Newly Diagnosed Myelodysplastic Syndromes: An International Prospective Observational Study By the Gimema

Evaluating the Impact of Cross-over from Imatinib to Nilotinib on the Overall Survival in Chronic Myeloid Leukemia Using Inverse Probability of Censoring Weighting: Results from the Gimema Sustrenim Study

Decitabine in older patients with AML: quality of life results of the EORTC-GIMEMA-GMDS-SG randomized phase 3 trial

Real World Outcome of Unfit Patients with Acute Myeloid Leukemia Treated with the Combination Venetoclax Plus Hypomethylating Agents in the Gimema AML2320 Observational Trial

Health-Related Quality of Life Profile and Symptom Burden of Patients with Aggressive B-Cell Lymphomas Just before CAR-T-Cell Therapy: A Real-World Study By the Gimema

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only